Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KEVIN R KELLY

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1093963712
CMS profile
140684
Location
LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$134,612.34

155 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KEVIN R KELLY

NPI 1093963712 · CMS profile ID 140684

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1093963712?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KEVIN R KELLY, NPI 1093963712, CMS profile ID 140684. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1093963712?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). KEVIN R KELLY, NPI 1093963712, CMS profile ID 140684. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1093963712?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
KEVIN R KELLY, NPI 1093963712, CMS profile ID 140684, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1093963712?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

155 matching records · $134,612.34 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 155 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 155.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $135.9809/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078307596 CMS
Janssen Biotech, Inc. $759.1609/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078305878 CMS
Janssen Biotech, Inc. $4,125.0009/17/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078308150 CMS
Janssen Biotech, Inc. $5.5009/13/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078307346 CMS
Janssen Biotech, Inc. $147.4309/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078308244 CMS
Janssen Biotech, Inc. $550.0009/06/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078306492 CMS
Janssen Biotech, Inc. $75.1808/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078307958 CMS
Janssen Biotech, Inc. $58.5808/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078309084 CMS
Janssen Biotech, Inc. $550.0008/28/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078309470 CMS
Lilly USA, LLC $1,600.0008/21/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135121577 CMS
Janssen Biotech, Inc. $229.4608/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078306184 CMS
Lilly USA, LLC $1,200.0008/19/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135113006 CMS
Lilly USA, LLC $3,200.0008/19/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135121575 CMS
Janssen Biotech, Inc. $245.7008/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078306900 CMS
Lilly USA, LLC $79.0708/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135121579 CMS
AstraZeneca Pharmaceuticals LP $2,750.0008/13/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105587028 CMS
Lilly USA, LLC $1,600.0008/05/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135131036 CMS
Janssen Biotech, Inc. $1,755.0007/31/2024 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1155140074 CMS
AstraZeneca Pharmaceuticals LP $4,100.0007/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104312150 CMS
AstraZeneca Pharmaceuticals LP $51.2507/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104378869 CMS
AstraZeneca Pharmaceuticals LP $119.3507/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104553930 CMS
AstraZeneca Pharmaceuticals LP $40.7806/27/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104612608 CMS
AstraZeneca Pharmaceuticals LP $152.9706/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104706787 CMS
Ipsen Biopharmaceuticals, Inc $4,830.0006/26/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091966764 CMS
Ipsen Biopharmaceuticals, Inc $150.0006/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091966766 CMS
Janssen Biotech, Inc. $4,125.0006/24/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078308810 CMS
Janssen Biotech, Inc. $913.5006/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078308928 CMS
Janssen Biotech, Inc. $100.7906/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078307842 CMS
Janssen Biotech, Inc. $5.5006/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078306572 CMS
Janssen Biotech, Inc. $101.5506/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078307358 CMS
Janssen Biotech, Inc. $3,575.0005/31/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078307130 CMS
Janssen Biotech, Inc. $145.0305/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078307028 CMS
Janssen Biotech, Inc. $10.0005/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078308716 CMS
Janssen Biotech, Inc. $45.5605/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078309048 CMS
Janssen Biotech, Inc. $33.2205/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078306564 CMS
Janssen Biotech, Inc. $22.2005/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078307088 CMS
Janssen Biotech, Inc. $57.0005/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078307256 CMS
Janssen Biotech, Inc. $38.9405/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078307676 CMS
Janssen Biotech, Inc. $63.7205/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078307774 CMS
Janssen Biotech, Inc. $25.0005/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078309016 CMS
Karyopharm Therapeutics Inc. $14.2904/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145532397 CMS
Karyopharm Therapeutics Inc. $69.0004/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145532408 CMS
Karyopharm Therapeutics Inc. $123.6904/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145532413 CMS
Karyopharm Therapeutics Inc. $5,000.0004/23/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145532417 CMS
Karyopharm Therapeutics Inc. $438.2104/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145532421 CMS
Karyopharm Therapeutics Inc. $7.9604/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145532426 CMS
Karyopharm Therapeutics Inc. $168.3504/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145532429 CMS
Karyopharm Therapeutics Inc. $46.3604/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145532437 CMS
Karyopharm Therapeutics Inc. $56.4604/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145532442 CMS
Janssen Biotech, Inc. $3,575.0004/22/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078308914 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $155,565.50 146
PY2020 $57,454.49 51
PY2021 $171,307.79 133
PY2022 $189,281.46 130
PY2023 $108,564.88 107
PY2024 $134,612.34 155
PY2025 $77,369.10 68

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $156,590.08 15
PY2024 Recipient $3,200.00 1
PY2024 Principal investigator $204,099.36 1
PY2023 Principal investigator $629,334.08 25
PY2022 Recipient $950.00 2
PY2022 Principal investigator $355,314.65 11
PY2021 Recipient $2,550.00 5
PY2021 Principal investigator $534,450.09 19
PY2020 Recipient $1,442.58 3
PY2020 Principal investigator $275,730.93 16
PY2019 Principal investigator $348,485.87 14

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

15 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 BeOne Medicines USA, Inc. $540.00 12/23/2025 Non-covered Recipient Entity
University of Southern California, Norris Comprehensive Cancer Center
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190332560
Principal investigator 1 BeOne Medicines Ltd. $33,536.00 12/17/2025 Non-covered Recipient Entity
University of Southern California, Norris Comprehensive Cancer Center
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190330667
Principal investigator 1 BeOne Medicines Ltd. $624.25 12/17/2025 Non-covered Recipient Entity
University of Southern California, Norris Comprehensive Cancer Center
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190330669
Principal investigator 1 BeOne Medicines Ltd. $33,536.00 12/17/2025 Non-covered Recipient Entity
University of Southern California, Norris Comprehensive Cancer Center
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190330671
Principal investigator 1 BeOne Medicines Ltd. $2,631.38 12/17/2025 Non-covered Recipient Entity
University of Southern California, Norris Comprehensive Cancer Center
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190330673
Principal investigator 1 BeOne Medicines Ltd. $624.25 12/17/2025 Non-covered Recipient Entity
University of Southern California, Norris Comprehensive Cancer Center
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190337859
Principal investigator 1 BeOne Medicines Ltd. $2,631.38 12/17/2025 Non-covered Recipient Entity
University of Southern California, Norris Comprehensive Cancer Center
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190337863
Principal investigator 1 BeOne Medicines Ltd. $624.25 12/17/2025 Non-covered Recipient Entity
University of Southern California, Norris Comprehensive Cancer Center
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190337868
Principal investigator 1 BeOne Medicines Ltd. $8,612.72 12/17/2025 Non-covered Recipient Entity
University of Southern California, Norris Comprehensive Cancer Center
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190337872
Principal investigator 1 BeOne Medicines Ltd. $624.25 12/17/2025 Non-covered Recipient Entity
University of Southern California, Norris Comprehensive Cancer Center
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190337877
Principal investigator 1 BeOne Medicines Ltd. $8,612.72 12/17/2025 Non-covered Recipient Entity
University of Southern California, Norris Comprehensive Cancer Center
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190337881
Principal investigator 1 ABBVIE INC. $28,005.00 12/04/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTHERN CALIFORNIA
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) No dispute reported 06/30/2026 1202527614
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $993.88 09/23/2025 Covered Recipient Teaching Hospital
KECK HOSPITAL OF USC
A RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF A+AVD VERSUS ABVD AS FRONTLINE THERAPY IN PATIENTS WITH ADVANCED CLASSICAL HODGKIN LYMPHOMA No dispute reported 06/30/2026 1223267145
Principal investigator 1 BeOne Medicines USA, Inc. $8,644.00 07/29/2025 Non-covered Recipient Entity
University of Southern California, Norris Comprehensive Cancer Center
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190332551
Principal investigator 1 BeOne Medicines USA, Inc. $26,350.00 07/15/2025 Non-covered Recipient Entity
University of Southern California, Norris Comprehensive Cancer Center
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies No dispute reported 06/30/2026 1190332556